Eris Lifesciences Q3 Results Review - In-Line; MR Productivity On An Uptrend: Motilal Oswal
Product mix and better operating leverage drive improved margins YoY.14-02-2024
14-02-2024
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
In accordance with the applicable requirements and regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable Regulations, we hereby inform you that the Recording of the Earnings Conference Call in connection with the Unaudited Consolidated and Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2023, held on February 13, 2024, is available on the website of the Company and can be accessed through the following link: Link: https://eris.co.in/financials/ (File name: Q3 FY24-Earnings Call Recording)13-02-2024
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor presentation under regulation 30(LODR)13-02-2024
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Issue of Securities
Issuance of 43750 8% Secured Redeemable Non-Convertible Debentures13-02-2024
Eris Lifesciences Ltd - 540596 - Financial Results For The Quarter And Nine Months Ended December 31, 2023
Financial Results for the quarter and nine months ended December 31, 202313-02-2024
Eris Lifesciences Ltd - 540596 - Board Meeting Outcome for OUTCOME OF THE BOARD MEETING
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III and SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., February 13, 2024, inter alia, duly approved/took on record the following: ? The limited reviewed unaudited Standalone & Consolidated Financial Results for the quarter and nine months ended December 31, 2023; ? Execution of Share Purchase and Shareholders' Agreement for acquisition of 51% equity stake in Swiss Parenterals Limited. ? Issuance of 43,750 8% Secured Redeemable Non-Convertible Debentures having face value of Rs. 1,00,000/- (Rupees One lakh) against the Equity Shares of Swiss Parenterals Limited on Private Placement Basis.13-02-2024
Eris Lifesciences Ltd - 540596 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for UTI Mutual Fund & PACs12-02-2024
Eris Lifesciences Ltd - 540596 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for UTI Mutual Fund08-02-2024
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING.07-02-2024
Eris Lifesciences Ltd - 540596 - VOLUNTARY DISCLOSURE
The assignment of credit rating to Eris Therapeutics Limited, Wholly Owned Subsidiary of the listed entity, by India Rating & Research.07-02-2024